EUCTR2007-002693-66-BG进行中（未招募）1 期
An Open-Label 5 Years-2nd Extension to: A phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc.0 个研究点目标入组 16,071 人开始时间: 2009年2月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16,071
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Second extension
- •In order to be eligible for participation in this trial, the subject must:
- •NOTE: Subjects inappropriately randomized into the trial (i.e., those who do not meet entry criteria) may be discontinued from the study at the discretion of the Sponsor.
- •1. Have met all initial inclusion criteria and ha ve not met any of the exclusion or discontinuation criteria of either the base or 1st extension studies.
- •NOTE: There is no specific BMD T-score required for eligibility in this extension study. If a subject has met excessive bone loss criteria at her end of study visit for the
- •1st extension study, or the 2nd extension screening visit, she can continue into this 2nd extension.
- •2. Be an active participant and have successfully completed the 1st extension study on study medication. (An interruption of approximately 12 weeks from the end of the first extension study to the begining of 2nd extension study is permissible).
- •3. Be assessed by the investigator as having had appropirate compliance during the base and 1st extension studies.
- •4. Have at least one hip (e.g. contains no hardware from or thopedic procedures) AND
- •suitable spinal anatomy that is evaluable by DXA.
- •5. Understand the study procedures, alternative treatments available, risks involved with the study, and voluntarily agree to participate by providing informed consent.
- •6. Be able to read, understand and complete questionnaires and diaries. NOTE: If a subject who understands the purpose and use of the diary
- •cards and study questionnaires is unable to complete these without assistance (e.g. due to visual problems, difficulty writing due to arthritis,
- •inability to read, etc.), a family member or care-giver may assist or may complete the diary card on her behalf
- •7. Be in generally good health, based on medical history, physical examination, and laboratory evaluation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5000
排除标准
- •Second extension:
- •The subject must be excluded from participating in the trial if the subject:
- •1. Has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the bes t interest of the subject to participate.
- •2. Is receiving treatment as follows:
- •1) Current use of osteoporosis therapy including: bisphosphonates, PTH, strontium, systemic estrogen + progestin, raloxifene or other SERM, RANK ligand inhibitor, or sub-cutaneous calcitonin. (Note: use of intranasal calcitonin is permitted.)
- •2) Subject is planning to initiate or is currently using long-term therapy (6 weeks or longer) with any CYP3A4 inducers (see Appendix 12.5 for examples).
- •3. Is, in the opinion of the investigator, mentally or legally incapacitated such that informed consent cannot be obtained or the subject cannot read or comprehend the written material.
- •4. Has participated in an investigational drug study other than the base study or 1st
- •extension study within the past 30 days.
- •5. Is currently a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence.
研究者
相似试验
进行中（未招募）
1 期
An Open-Label 5-Year 2nd Extension for 5 years to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumMedDRA version: 19.0 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2007-002693-66-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A.16,071
进行中（未招募）
1 期
A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumPostmenopausal OsteoporosisEUCTR2011-005514-10-LTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.8,254
进行中（未招募）
1 期
Extension to the Odanacatib Fracture Trial (PN018)MedDRA version: 17.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersosteoporosisEUCTR2014-002587-33-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.16,071
进行中（未招募）
1 期
An Open-Label 5-Year 2nd Extension to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumMedDRA version: 17.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2007-002693-66-EEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.8,254
已完成
不适用
A 5-YEAR OPEN LABEL EXTENSION TO: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF ODANACATIB (MK-0822) IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSISPER-075-10MERCK SHARP & DOHME PERU S.R.L.,3